Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters

References

• Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, Witters LA, Ismail-Beigi F. (2000). Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 380(2):347–352.
   Google Scholar
• Ahren B. (2008). Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 4(2):383–394.
   Google Scholar
• Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, Stearns RA, Vincent SH. (2007). Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35(4):525–532.
   Google Scholar
• Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59(5):1277–1286.
   Google Scholar
• Choi MK, Jin QR, Jin HE, Shim CK, Cho DY, Shin JG, Song IS. (2007). Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos 28(9):501–510.
   Google Scholar
• Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. (2007). Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321(2):673–683.
   Google Scholar
• Grant RW, Pirraglia PA, Meigs JB, Singer DE. (2004). Trends in complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 164(10):1134–1139.
   Google Scholar
• Green J, Feinglos M. (2008). New combination treatments in the management of diabetes: focus on sitagliptin–metformin. Vasc Health Risk Manag 4(4):743–751.
   Google Scholar
• Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. (2009). Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets 10(1):71–87.
   Google Scholar
• Herman GA, Bergman A, Yi B, Kipnes M. (2006). Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 22(10):1939–1947.
   Google Scholar
• Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davis MJ, Ramael S, Gottesdiener KM, Wagner JA. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78(6):675–688.
   Google Scholar
• Jin HE, Hong SS, Choi MK, Maeng HJ, Kim DD, Chung SJ, Shim CK. (2009). Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis. Pharm Res 26(3):549–559.
   Google Scholar
• Kao DP, Kohrt HE, Kugler J. (2008). Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25(10):1229–1230.
   Google Scholar
• Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2005). (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48(1):141–151.
   Google Scholar
• Kimura N, Okuda M, Inui K. (2005). Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 22(2):255–259.
   Google Scholar
• Shin HJ, Lee CH, Park SJ, Shin JG, Song IS. (2010). Establishment and characterization of Mardin-Darby canine kidney cells stably expressing human organic anion transporters. Arch Pharm Res 33(5):709–716.
   Google Scholar
• Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM. (2007). Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117(5):1422–1431.
   Google Scholar
• Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23(5):545–551.
   Google Scholar
• Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. (1981). Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12(2):235–246.
   Google Scholar
• Ullrich KJ, Rumrich G, David C, Fritzsch G. (1993). Bisubstrates: substances that interact with renal contraluminal organic anion and organic cation transport systems. I. Amines, piperidines, piperazines, azepines, pyridines, quinolines, imidazoles, thiazoles, guanidines and hydrazines. Pflugers Arch 425(3–4):280–299.
   Google Scholar
• Urakami Y, Okuda M, Saito H, Inui K. (2000). Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett 473(2):173–176.
   Google Scholar
• Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35(4):533–538.
   Google Scholar
• Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. (2003). Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 63(4):844–848.
   Google Scholar
• Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA. (2004). AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279(46):47898–49905.
   Google Scholar
• Zhang L, Schaner ME, Giacomini KM. (1998). Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286(1):354–361.
   Google Scholar
• Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167–1174.
   Google Scholar